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Transcriptional control: How nuclear receptors get turned on
John W.R. Schwabe
The recently determined structures of the ligand-
binding domains from three nuclear receptors show
that  a receptor undergoes a significant conformational
change on ligand binding. It is not yet clear how this
structural change results in transcriptional activation.
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Ten years or so ago, it had begun to look as if the
techniques of structural biology were unlikely to
contribute greatly to our understanding of how the pro-
teins that bind to the ‘enhancer’ elements that regulate the
expression of eukaryotic genes actually activate transcrip-
tion. Although there was evidence that such transcriptional
activators operate through protein–protein contacts with
other components of the transcriptional machinery, these
interactions appeared to be transient, and not to involve
well-structured intermolecular interfaces between proteins
in a stoichiometric transcription complex.
This view was based essentially on four observations.
Firstly, enhancers can regulate promoters in a manner that
is more or less independent of their relative orientation
and the length of DNA between them (indeed, this was
how they were originally defined). Secondly, the greater
the number of enhancers a gene possesses, the higher its
level of transcription. Thirdly, artificial transcription
factors, such as chimaeras of domains from various other
transcription factors, seem able to activate transcription
very effectively via DNA-binding sites that function as
enhancers. Lastly, synthetic polypeptides with totally arti-
ficial sequences, particularly those with a net negative
charge, can also act as effective transcriptional activators.
These observations led to the use of terms such as ‘acid
blob’ to describe transactivation domains — enough to
frighten off any structural biologist. Indeed, in 1988 even
structural biologists were convinced that transcriptional
activation was the work of ‘negative noodles’ and need not
depend upon fixed structural interactions [1]. In the fol-
lowing years however, it became clear that, for some genes
at least, transcriptional activation does in fact require the
formation of highly ordered, “stereospecific transcriptional
complexes” [2].
The recently determined crystal structures of the ligand-
binding domains of three nuclear receptors [3–5] bring the
‘structure versus noodle’ issue into sharper focus. The
nuclear receptors, which include the steroid hormone
receptors, are an important family of transcription factors
involved in regulating a wide range of cellular processes
(reviewed in [6]). In simple terms, the nuclear receptors
bind to specific DNA sequences associated with their
target genes, and activate transcription on binding their
specific ligand. The best studied receptors bind to DNA
as dimers — either as homodimers or as heterodimers with
a common partner, the retinoid X receptor (RXR). The
receptors are composed of three main parts, the most
highly conserved of which is the central DNA-binding
domain. The structures of the DNA-binding domains
from several different receptors, bound to their DNA
targets, have been determined (Fig. 1) [7–9].
The less well conserved, carboxy-terminal domain of a
nuclear receptor has ligand-binding, dimerization and
transactivation functions. At the other end of the protein,
the region on the amino-terminal side of the DNA-binding
domain is highly variable in sequence, and in some recep-
tors this region contains a second transactivation domain.
The DNA-binding and ligand-binding domains appear to
be flexibly linked, discrete functional domains that can be
used out of context to construct artificial proteins. Further
dissection of the ligand-binding domain has suggested that
19 residues near the carboxyl terminus — termed the AF-2
or tc domain — have a separable activation function, as,
remarkably, these few residues retain enhancer activity
when linked to a heterologous DNA-binding domain (see
[10], for example).
A molecular switch
Crystallographic analysis of the unliganded ligand-binding
domain of RXRa [3] showed that the protein is a homo-
dimer, each subunit of which is composed of 12 a helices
arranged in three layers (Fig. 1). (Note that helix 11 in the
original paper has been re-interpreted to be composed of
two helices.) The AF-2 domain forms a helix — helix 12
— that protrudes away from the rest of the protein and is
exposed to solvent. Two large hydrophobic cavities in the
structure (unusual in a folded protein) may form the
hormone-binding pocket — each is large enough to
accommodate the ligand (9-cis retinoic acid). 
Recently, the crystal structures have been determined of
the liganded forms of the ligand-binding domains of two
other members of the nuclear receptor family — the
retinoic acid receptor (RARg) [4] and the thyroid
hormone receptor (TRa) [5]. Sequence alignments based
on knowledge of the three structures suggest that the
unliganded forms of the RARg and TRa ligand-binding
domains are likely to have similar conformations to the
unliganded RXRa ligand-binding domain [11]. If this is
true, it suggests that, on binding ligand, the receptors
undergo a considerable conformational change, involving
a major rearrangement of two regions of the protein
(helices 2–3 and 11–12, see Fig. 1). Helix 2 is not present
in the liganded receptors, and helix 3 is shifted and bent
in toward the core of the protein. Helix 11 moves out of
the core of the protein, making room for the ligand, which
binds in a single hydrophobic pocket; helix 12 folds back
and caps this pocket. Overall these conformational
changes result in  the liganded domain having a more
compact structure.
In both liganded structures, the ligand-binding domain is
monomeric — in contrast with the dimeric, unliganded
RXRa. This may, however, reflect the surface chemistry
of the different  ligand-binding domains, rather than being
a consequence of the conformational change, as the region
of the protein that forms the dimer interface in the RXRa
homodimer (helices 9 and 10) is relatively unperturbed on
binding ligand (Fig. 1). Thus, the conformational change
primarily affects what would be the surface of a dimeric
ligand-binding domain. It is likely that the existing struc-
tures hold some clue as to why the ligand-binding
domains of TRa and RARg do not homodimerize (at least
in the crystal), and whether the protein–protein interface
in heterodimers involving RXR is likely to resemble that
in the unliganded RXRa homodimer. For the biology of
the system, it is very important to understand whether
ligand-binding to one subunit of a dimer affects dimeriza-
tion or ligand-binding to the other subunit. Answering
these questions, however, may require structural analysis
of receptor heterodimers.
A molecular mousetrap?
The binding of all-trans retinoic acid to RARg has been
likened to a mouse being caught by a trap. In many ways
this is a good analogy. The mouse is attracted to the trap —
in this case by the receptor’s electrostatic potential. Once
the ligand enters the trap, the mechanism is triggered and a
conformational change takes place, preventing the ligand’s
exit. In the same way that the sprung mouse trap is more
stable than the primed trap, it seems that ligand binding to
the RARg and TRa ligand-binding domains stabilizes
their structures relative to the unliganded RXRa ligand-
binding domain. The hormone clearly forms an integral
part of the hydrophobic core of the liganded domain.
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Figure 1
A heterodimer of RXR (red) and a partner nuclear receptor (blue)
before (top) and after (bottom) ligand binding. In the heterodimer, the
DNA-binding domains (DBDs) are arranged head-to-tail, and the
ligand-binding domains (LBDs) are arranged head-to-head; the amino-
terminal domains (ABDs) are also shown. The insets show the ligand-
binding domains of unliganded RXRa (top) and liganded RARg
(middle) [11] and the DNA-binding domains of the RXR and TR bound
to DNA (bottom) [9]. Note that the figure suggests that both ligand-
binding domains bind ligand at the same time, and that there is a
concerted confromational change in both ligand-binding domains: this
may or may not be true and requires further experimental investigation.
The relationship between the DNA-binding and ligand-binding domains
also remains to be established.
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This stabilization on ligand binding, however, in itself
presents a problem. Mouse traps are one-way contrap-
tions. Even if the trap is the kind that spares the life of
the mouse, the mouse has to be freed by some outside
intervention; the trap cannot reset itself. In the case of
the  ligand-binding domains, however, the trap clearly has
to be reversible. A permanently active receptor would not
be useful. Indeed, in vitro experiments indicate that fresh
ligand can effectively compete with pre-bound ligand.
This means that, despite the apparently higher structural
stability of the liganded receptor, there must be an equi-
librium that allows the ligand to dissociate from the
protein, although this need not necessarily require a con-
tinual structural flip–flop. Wagner et al. [5] suggest that
helix 12 may only loosely cover the ligand binding
pocket, which may provide a way out for the ligand,
although there may also be access from the other end of
the pocket.
What does the switch do?
Although one must be somewhat cautious, as no single
ligand-binding domain has yet been observed both with
and without ligand, the comparison of liganded and unli-
ganded receptors appears to show us a molecular switch
in action. Although these structures give us beautiful
images of nature at work, they raise the question of what
happens next. You can flip the little plastic lever, but why
does the light come on? We still need to understand the
wiring between the ligand-binding domain and the
general transcriptional complex.
Much attention must focus on the AF-2 domain. The
structural change on binding ligand suggests that activa-
tion of nuclear receptors requires a specific conforma-
tional change, recognized through specific interactions
with other proteins. If this is the case, it seems surprising
that the AF-2 domain can serve as an activator of
transcription when excised from the rest of the protein
and linked to a heterologous DNA-binding domain It also
seems strange that, in the unliganded receptor, the AF-2
domain is completely exposed, yet does not activate
transcription.
Looking beyond the  ligand-binding domain itself, in the
last few years molecular biologists have been remarkably
successful in identifying accessory proteins that differen-
tially recognize the liganded and unliganded receptors.
These are termed co-activators (for example, [12]) and co-
repressors (for example, [13]), respectively. The discov-
ery of these factors suggests that the role of the
conformational change on ligand binding is to induce
release of the co-repressor and binding of a co-activator.
The fact that these interactions are strong enough to be
demonstrated in vitro suggests that the nature of the
ternary complexes may be tackled using the techniques
of structural biology.
Conclusions
Nuclear receptors have turned out to be a structural
biologist’s dream. The structures of their DNA-binding
domains complexed with DNA have provided a stereo-
chemical understanding of how the receptors can recog-
nize and discriminate the sequence and structure of their
DNA targets. The structures of their ligand-binding
domains have shown, in precise atomic detail, a molecular
switch at work. The structures of additional ligand-
binding domains, especially heterodimers, will no doubt
fill in the many remaining details. Further structural work
should answer important questions about the relationship
between the ligand-binding and DNA-binding domains in
full-length receptor dimers bound to DNA. Finally,
further in the future, there is hope that structures of
ternary complexes, involving co-repressors or co-activa-
tors, will give a clearer idea of what it is exactly that the
molecular switch triggers and may clarify the relative
importance of defined structure on the one hand, and
blob/noodle flexibility on the other, in transcriptional
activation domains.
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